Women in the field of multiple sclerosis: How they contributed to paradigm shifts

• Published in: Frontiers in molecular neuroscience Vol. 16; p. 1087745
• Main Authors: Barateiro, Andreia, Barros, Catarina, Pinto, Maria V, Ribeiro, Ana Rita, Alberro, Ainhoa, Fernandes, Adelaide
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Research Foundation 03-02-2023; Frontiers Media S.A
• Subjects: Axons; Central nervous system; Clinical trials; Cognition & reasoning; Cognitive ability; cognitive impairment (CI); Communications systems; Demyelination; Disability; Epstein-Barr virus; immune cell response; Infections; Information processing; Intestinal microflora; Lymphocytes B; Lymphocytes T; Macrophages; Medical research; Memory; miRNA; Multiple sclerosis; Myelin; Myelination; Neural networks; Neuroscience; Paradigms; Pathology; Pathophysiology; peripheral-CNS interplay; Quality of life; Substantia alba; Substantia grisea; white and gray matter damage; Women; cognitive impairment (CI); white and gray matter damage; peripheral-CNS interplay; immune cell response; multiple sclerosis
• ISSN: 1662-5099; 1662-5099
• DOI: 10.3389/fnmol.2023.1087745

History is full of women who made enormous contributions to science. While there is little to no imbalance at the early career stage, a decreasing proportion of women is found as seniority increases. In the multiple sclerosis (MS) field, 44% of first authors and only 35% of senior authors were female. So, in this review, we highlight ground-breaking research done by women in the field of MS, focusing mostly on their work as principal investigators. MS is an autoimmune disorder of the central nervous system (CNS), with evident paradigm shifts in the understating of its pathophysiology. It is known that the immune system becomes overactivated and attacks myelin sheath surrounding axons. The resulting demyelination disrupts the communication signals to and from the CNS, which causes unpredictable symptoms, depending on the neurons that are affected. Classically, MS was reported to cause mostly physical and motor disabilities. However, it is now recognized that cognitive impairment affects more than 50% of the MS patients. Another shifting paradigm was the involvement of gray matter in MS pathology, formerly considered to be a white matter disease. Additionally, the identification of different T cell immune subsets and the mechanisms underlying the involvement of B cells and peripheral macrophages provided a better understanding of the immunopathophysiological processes present in MS. Relevantly, the gut-brain axis, recognized as a bi-directional communication system between the CNS and the gut, was found to be crucial in MS. Indeed, gut microbiota influences not only different susceptibilities to MS pathology, but it can also be modulated in order to positively act in MS course. Also, after the identification of the first microRNA in 1993, the role of microRNAs has been investigated in MS, either as potential biomarkers or therapeutic agents. Finally, concerning MS therapeutical approaches, remyelination-based studies have arisen on the spotlight aiming to repair myelin loss/neuronal connectivity. Altogether, here we emphasize the new insights of remarkable women that have voiced the impact of cognitive impairment, white and gray matter pathology, immune response, and that of the CNS-peripheral interplay on MS diagnosis, progression, and/or therapy efficacy, leading to huge breakthroughs in the MS field.